AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27151607 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVR (both devices)
Number of subjects: 848
Study 27151609 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated balloons
Number of subjects: 105
Study 27151914 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell-assisted lipotransfer using freshly isolated autologous adipose-derived stromal cells (4.07 × 10(7) cells with 10 ml of lipoaspirate)
Number of subjects: 1
Study 27151994 — intervention group
Group type: EXPERIMENTAL
Intervention: Entinostat (10 or 15 mg oral entinostat once every other week)
Number of subjects: 49
Study 27151994 — intervention group
Group type: EXPERIMENTAL
Intervention: Entinostat (15 mg oral entinostat once weekly in 3 of 4 weeks)
Number of subjects: 49
Study 27151994 — intervention group
Group type: EXPERIMENTAL
Intervention: Entinostat
Number of subjects: 49
Study 27152482 — intervention group
Group type: COMPARATOR
Intervention: Montelukast (placebo-controlled trial)
Number of subjects: 343
Study 27152501 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY-TT
Number of subjects: 539
Study 27152501 — intervention group
Group type: COMPARATOR
Intervention: Men-PS
Number of subjects: 539
Study 27152857 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy during radiation for PET nonresponders who changed chemotherapy (38 patients)
Number of subjects: 201
Study 27152857 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy during radiation for PET responders (113 patients)
Number of subjects: 201
Study 27152857 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy during radiation for PET nonresponders who did not change chemotherapy (50 patients)
Number of subjects: 201
Study 27152857 — intervention group
Group type: EXPERIMENTAL
Intervention: PET responders (113 patients)
Number of subjects: 201
Study 27152857 — intervention group
Group type: COMPARATOR
Intervention: PET nonresponders who did not change chemotherapy (50 patients)
Number of subjects: 201
Study 27152857 — intervention group
Group type: EXPERIMENTAL
Intervention: PET nonresponders who changed chemotherapy (38 patients)
Number of subjects: 201
Study 27153246 — intervention group
Group type: EXPERIMENTAL
Intervention: faldaprevir 120 mg q.d. for 12 or 24 weeks plus PegIFNα-2b/RBV for 24 or 48 weeks
Number of subjects: 131
Study 27153246 — intervention group
Group type: EXPERIMENTAL
Intervention: faldaprevir 240 mg q.d. for 12 weeks plus PegIFNα-2b/RBV for 24 or 48 weeks
Number of subjects: 131
Study 27153246 — intervention group
Group type: EXPERIMENTAL
Intervention: faldaprevir 240 mg q.d. for 24 weeks plus PegIFNα-2b/RBV for 24 or 48 weeks
Number of subjects: 131
Study 27153246 — intervention group
Group type: EXPERIMENTAL
Intervention: faldaprevir 240 mg q.d. for 24 weeks plus PegIFNα-2b/RBV for 48 weeks
Number of subjects: 131
Study 27153246 — intervention group
Group type: COMPARATOR
Intervention: faldaprevir 120 mg q.d. plus PegIFNα-2b/RBV
Number of subjects: 131
Study 27153752 — intervention group
Group type: EXPERIMENTAL
Intervention: EHR patient portal message promoting influenza vaccines and offering online appointment scheduling
Number of subjects: 30000
Study 27153752 — intervention group
Group type: EXPERIMENTAL
Intervention: IVR call with similar content but without appointment facilitation
Number of subjects: 30000
Study 27153752 — intervention group
Group type: EXPERIMENTAL
Intervention: Both EHR patient portal message and IVR call
Number of subjects: 30000
Study 27153752 — intervention group
Group type: COMPARATOR
Intervention: Neither EHR patient portal message nor IVR call (usual care)
Number of subjects: 30000
Study 27154507 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported questionnaires at 1 week, and 1, 3, 6, 12, and 24 months after injury.
Number of subjects: 0
Study 27154507 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed models analysis.
Number of subjects: 0
Study 27154507 — intervention group
Group type: EXPERIMENTAL
Intervention: Outcome prediction model development.
Number of subjects: 0
Study 27154719 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated protein C (DAA) 24 mg/kg/h for 96 h
Number of subjects: 1241
Study 27154719 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone 50 mg intravenous bolus q6 for 7 days
Number of subjects: 1241
Study 27154719 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludrocortisone 50 µg once daily for 7 days
Number of subjects: 1241
Study 27154719 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of DAA and corticosteroids
Number of subjects: 1241
Study 27154719 — intervention group
Group type: COMPARATOR
Intervention: Placebo for DAA
Number of subjects: 1241
Study 27154719 — intervention group
Group type: COMPARATOR
Intervention: Placebo for corticosteroids
Number of subjects: 1241
Study 27154907 — intervention group
Group type: EXPERIMENTAL
Intervention: Project SEARCH plus Autism Spectrum Disorder Supports
Number of subjects: 49
Study 27154907 — intervention group
Group type: COMPARATOR
Intervention: High school special education services as usual
Number of subjects: 49
Study 27154915 — intervention group
Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin plus R-CVP (rituximab, cyclophosphamide, vincristine, and prednisone)
Number of subjects: 48
Study 27154915 — intervention group
Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin plus R-CVP
Number of subjects: 48
Study 27154971 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smoking defined using both self-report and eCO concentrations
Number of subjects: 573
Study 27154971 — intervention group
Group type: COMPARATOR
Intervention: Current smoking defined using self-report or eCO
Number of subjects: 573
Study 27155023 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram treatment
Number of subjects: 0
Study 27155023 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 27156227 — intervention group
Group type: EXPERIMENTAL
Intervention: Onalespib (AT13387) 150-220 mg/m² once-weekly intravenous for 3 weeks and imatinib 400 mg daily
Number of subjects: 26
Study 27156227 — intervention group
Group type: EXPERIMENTAL
Intervention: Onalespib (AT13387) plus imatinib
Number of subjects: 26
Study 27157491 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (10 mg/kg intravenously every 2 weeks for 24 months)
Number of subjects: 39
Study 27158500 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO-KLAT2.0 (youth)
Number of subjects: 46
Study 27158500 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-36 Physical Component Summary (PCS) (youth)
Number of subjects: 46
Study 27158500 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-36 Mental Component Summary (MCS) (youth)
Number of subjects: 46
Study 27158500 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemo-QoL-A (young adults)
Number of subjects: 46
Study 27158500 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-36 Physical Component Summary (PCS) (young adults)
Number of subjects: 46
Study 27158500 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-36 Mental Component Summary (MCS) (young adults)
Number of subjects: 46
Study 27158500 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint status as assessed by HJHS
Number of subjects: 46
Study 27158500 — intervention group
Group type: EXPERIMENTAL
Intervention: History of lifelong prophylaxis
Number of subjects: 46
Study 27158520 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized glycemic control (OPT group)
Number of subjects: 40
Study 27158520 — intervention group
Group type: COMPARATOR
Intervention: Non-optimized glycemic control (non-OPT group)
Number of subjects: 40
Study 27158520 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 27158544 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG 3350 17 g once daily for 7 days
Number of subjects: 203
Study 27158544 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 203
Study 27159194 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% protein diet (low protein)
Number of subjects: 20
Study 27159194 — intervention group
Group type: EXPERIMENTAL
Intervention: 15% protein diet (normal protein)
Number of subjects: 20
Study 27159194 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% protein diet (high protein)
Number of subjects: 20
Study 27159194 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline measurements)
Number of subjects: 20
Study 27159194 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall effect of overfeeding (all protein levels)
Number of subjects: 20
Study 27160012 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow mesenchymal stromal cells (MSC) infused into the cerebral arteries.
Number of subjects: 5
Study 27160286 — intervention group
Group type: EXPERIMENTAL
Intervention: UGT1A1*6, UGT1A1*28, rs1800469 and rs3087465
Number of subjects: 160
Study 27160286 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel genetic score model (cut off value of 1.5)
Number of subjects: 160
Study 27160356 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI at Week 14 post-NACRT
Number of subjects: 35
Study 27160692 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Aspergillus culture (PAC) group
Number of subjects: 85
Study 27160692 — intervention group
Group type: COMPARATOR
Intervention: Only positive galactomannan (OPG) group
Number of subjects: 85
Study 27160692 — intervention group
Group type: EXPERIMENTAL
Intervention: PAC group
Number of subjects: 85
Study 27160692 — intervention group
Group type: COMPARATOR
Intervention: OPG group
Number of subjects: 85
Study 27160944 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 0
Study 27160947 — intervention group
Group type: EXPERIMENTAL
Intervention: Apalutamide 240mg/d
Number of subjects: 51
Study 27161025 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast eating
Number of subjects: 75
Study 27161025 — intervention group
Group type: COMPARATOR
Intervention: Breakfast skipping
Number of subjects: 75
Study 27161178 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg
Number of subjects: 5171
Study 27161178 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 0.75 mg
Number of subjects: 5171
Study 27161178 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg and 0.75 mg
Number of subjects: 5171
Study 27161848 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarcopenic obesity (SO) in patients with COPD
Number of subjects: 2548
Study 27161848 — intervention group
Group type: COMPARATOR
Intervention: Normal body composition in patients with COPD
Number of subjects: 2548
Study 27161867 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior lateral meniscectomy
Number of subjects: 1205
Study 27161867 — intervention group
Group type: EXPERIMENTAL
Intervention: Current grade 3 to 4 trochlear articular cartilage changes
Number of subjects: 1205
Study 27161867 — intervention group
Group type: COMPARATOR
Intervention: Meniscal or articular cartilage pathologic changes
Number of subjects: 1205
Study 27161955 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydropyrimidine dehydrogenase (DPD) activity in PBMCs
Number of subjects: 20
Study 27161955 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymidylate synthase (TS) activity in PBMCs
Number of subjects: 20
Study 27161955 — intervention group
Group type: EXPERIMENTAL
Intervention: DHU : U plasma ratio
Number of subjects: 20
Study 27162131 — intervention group
Group type: EXPERIMENTAL
Intervention: (18)F-fluorocholine (18F-FCH) uptake in ipsilateral symptomatic carotid plaques
Number of subjects: 10
Study 27162131 — intervention group
Group type: EXPERIMENTAL
Intervention: (18)F-fluorocholine (18F-FCH) uptake
Number of subjects: 10
Study 27162212 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiographic Core Laboratory (ACL) assessment
Number of subjects: 329
Study 27162212 — intervention group
Group type: COMPARATOR
Intervention: Clinical Event Committee (CEC) assessment
Number of subjects: 329
Study 27162212 — intervention group
Group type: COMPARATOR
Intervention: Local Investigators (LIs) assessment
Number of subjects: 329
Study 27162226 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin analogues (PGAs)
Number of subjects: 35
Study 27162632 — intervention group
Group type: EXPERIMENTAL
Intervention: Riociguat
Number of subjects: 0
Study 27162632 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27163539 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal transplanted patients with pretransplant cancer
Number of subjects: 95
Study 27163539 — intervention group
Group type: COMPARATOR
Intervention: Control group (European patients without pretransplant cancer)
Number of subjects: 95
Study 27163539 — intervention group
Group type: COMPARATOR
Intervention: Control group (entire renal transplanted population in Uppsala)
Number of subjects: 95
Study 27163758 — intervention group
Group type: EXPERIMENTAL
Intervention: FIRM only (group 1)
Number of subjects: 113
Study 27163758 — intervention group
Group type: EXPERIMENTAL
Intervention: FIRM + PVAI (group 2)
Number of subjects: 113
Study 27163758 — intervention group
Group type: EXPERIMENTAL
Intervention: PVAI + posterior wall + non-PV trigger ablation (group 3)
Number of subjects: 113
Study 27163948 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Blood Management (PBM) program including preoperative optimization of hemoglobin levels, blood-sparing techniques, and standardization of transfusion practice.
Number of subjects: 129719
Study 27163948 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Blood Management (PBM) program
Number of subjects: 129719
Study 27164015 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine administration
Number of subjects: 50
Study 27165419 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary exercise testing (CPET)
Number of subjects: 34
Study 27165613 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated radiotherapy with carbogen and nicotinamide (ARCON)
Number of subjects: 345
Study 27165613 — intervention group
Group type: COMPARATOR
Intervention: Accelerated radiotherapy alone (AR)
Number of subjects: 345
Study 27165710 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 4935
Study 27165710 — intervention group
Group type: COMPARATOR
Intervention: Heparin±GPI
Number of subjects: 4935
Study 27165786 — intervention group
Group type: EXPERIMENTAL
Intervention: Mecillinam (400 mg pivmecillinam hydrochloride three times a day for 7 days)
Number of subjects: 20
Study 27165892 — intervention group
Group type: EXPERIMENTAL
Intervention: Visuospatial memory domain deficit
Number of subjects: 74
Study 27165892 — intervention group
Group type: EXPERIMENTAL
Intervention: Language domain deficit
Number of subjects: 74
Study 27165960 — intervention group
Group type: COMPARATOR
Intervention: Post-neonatal arterial ischemic stroke children with severe contralesional hand motor deficit
Number of subjects: 37
Study 27165960 — intervention group
Group type: COMPARATOR
Intervention: Post-neonatal arterial ischemic stroke children with good manual dexterity
Number of subjects: 37
Study 27165960 — intervention group
Group type: EXPERIMENTAL
Intervention: Contralesional hand performance
Number of subjects: 37
Study 27166296 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysomnography (PSG)
Number of subjects: 15
Study 27166673 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab monotherapy
Number of subjects: 35
Study 27167022 — intervention group
Group type: EXPERIMENTAL
Intervention: Single ventricle lesions after arch reconstruction
Number of subjects: 326
Study 27167022 — intervention group
Group type: EXPERIMENTAL
Intervention: Single ventricle lesions with gothic arch geometry
Number of subjects: 326
Study 27167022 — intervention group
Group type: EXPERIMENTAL
Intervention: Single ventricle lesions with right ventricle-pulmonary artery shunt
Number of subjects: 326
Study 27167022 — intervention group
Group type: EXPERIMENTAL
Intervention: Single ventricle lesions with aortic atresia
Number of subjects: 326
Study 27167022 — intervention group
Group type: EXPERIMENTAL
Intervention: Single ventricle lesions with recoarctation
Number of subjects: 326
Study 27167056 — intervention group
Group type: EXPERIMENTAL
Intervention: iSYS
Number of subjects: 911
Study 27167056 — intervention group
Group type: EXPERIMENTAL
Intervention: LIAISON XL
Number of subjects: 911
Study 27167056 — intervention group
Group type: EXPERIMENTAL
Intervention: IMMULITE
Number of subjects: 911
Study 27167056 — intervention group
Group type: EXPERIMENTAL
Intervention: IGFI RIACT
Number of subjects: 911
Study 27167056 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediagnost ELISA
Number of subjects: 911
Study 27167056 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediagnost RIA
Number of subjects: 911
Study 27167056 — intervention group
Group type: COMPARATOR
Intervention: All assays
Number of subjects: 911
Study 27167058 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative fluid challenge with 10 ml/kg of 0.9% normal saline
Number of subjects: 31
Study 27167058 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic preload variables
Number of subjects: 31
Study 27167058 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular tone variables
Number of subjects: 31
Study 27167209 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral macrolides after an initial 4-week IV amikacin and cefoxitin (or imipenem) treatment
Number of subjects: 71
Study 27167209 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral macrolides after an initial 2-week IV amikacin and cefoxitin (or imipenem) treatment
Number of subjects: 71
Study 27168432 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic current or former smokers (CAT score ≥10)
Number of subjects: 2736
Study 27168432 — intervention group
Group type: COMPARATOR
Intervention: Asymptomatic current or former smokers (CAT score <10)
Number of subjects: 2736
Study 27168432 — intervention group
Group type: COMPARATOR
Intervention: Controls who never smoked
Number of subjects: 2736
Study 27168432 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic current or former smokers
Number of subjects: 2736
Study 27168433 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver support interventions (not specified in detail)
Number of subjects: 280
Study 27168433 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver characteristics (younger age, less social support, etc.)
Number of subjects: 280
Study 27168844 — intervention group
Group type: EXPERIMENTAL
Intervention: DL-3-n-butylphthalide (NBP)
Number of subjects: 60
Study 27168844 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrolysin
Number of subjects: 60
Study 27168844 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 27168844 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between NBP and Cerebrolysin
Number of subjects: 60
Study 27169380 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based salt reduction program
Number of subjects: 572
Study 27169385 — intervention group
Group type: EXPERIMENTAL
Intervention: Evofosfamide (Arm A) - 30-60 min/day infusion on Days 1-5 of a 21-day cycle
Number of subjects: 49
Study 27169385 — intervention group
Group type: EXPERIMENTAL
Intervention: Evofosfamide (Arm B) - Continuous infusion over 120 hr on Days 1-5 of a 21-day cycle
Number of subjects: 49
Study 27169478 — intervention group
Group type: EXPERIMENTAL
Intervention: Isavuconazole (ISAV) 200 mg 3 times daily for 2 days followed by 200 mg once-daily (IV or PO)
Number of subjects: 38
Study 27169478 — intervention group
Group type: EXPERIMENTAL
Intervention: Isavuconazole (ISAV)
Number of subjects: 38
Study 27169571 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary/integrative medicine (CIM) treatment
Number of subjects: 70
Study 27169571 — intervention group
Group type: COMPARATOR
Intervention: Standard supportive care (Control)
Number of subjects: 70
Study 27169792 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg everolimus once daily
Number of subjects: 42
Study 27169832 — intervention group
Group type: EXPERIMENTAL
Intervention: Adequate WDDS (WDDS ≥4)
Number of subjects: 432
Study 27169832 — intervention group
Group type: COMPARATOR
Intervention: Inadequate WDDS (WDDS <4)
Number of subjects: 432
Study 27169833 — intervention group
Group type: EXPERIMENTAL
Intervention: Low energy flux
Number of subjects: 229
Study 27169833 — intervention group
Group type: EXPERIMENTAL
Intervention: High energy flux
Number of subjects: 229
Study 27169833 — intervention group
Group type: COMPARATOR
Intervention: Caloric restriction
Number of subjects: 229
Study 27169903 — intervention group
Group type: EXPERIMENTAL
Intervention: Cenicriviroc 150 mg once daily for 14 days
Number of subjects: 30
Study 27169903 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched controls)
Number of subjects: 30
Study 27170068 — intervention group
Group type: EXPERIMENTAL
Intervention: 4F-PCC 25 unit/kg
Number of subjects: 12
Study 27170068 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 12
Study 27170150 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurant Stent Graft system
Number of subjects: 1263
Study 27170150 — intervention group
Group type: EXPERIMENTAL
Intervention: SVS/AAVS 3 group
Number of subjects: 1263
Study 27170150 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 1263
Study 27170910 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprachoroidal retinal prosthesis with a highly configurable external neurostimulator delivering charge-balanced, constant-current biphasic pulses.
Number of subjects: 1
Study 27170910 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprachoroidal retinal prosthesis with a highly configurable external neurostimulator.
Number of subjects: 1
Study 27171141 — intervention group
Group type: EXPERIMENTAL
Intervention: HCoVs detection in children with febrile seizures (FS)
Number of subjects: 874
Study 27171141 — intervention group
Group type: EXPERIMENTAL
Intervention: HCoVs detection in children with acute gastroenteritis (AGE)
Number of subjects: 874
Study 27171141 — intervention group
Group type: EXPERIMENTAL
Intervention: HCoVs detection in children with acute bronchiolitis (AB)
Number of subjects: 874
Study 27171141 — intervention group
Group type: COMPARATOR
Intervention: HCoVs detection in healthy controls
Number of subjects: 874
Study 27171141 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-detection of other viruses in children with AB
Number of subjects: 874
Study 27171141 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-detection of other viruses in children with FS
Number of subjects: 874
Study 27171141 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-detection of other viruses in children with AGE
Number of subjects: 874